Early research (Phase 1)Study completedNCT06336018What this trial is testingA Research Study on Etavopivat in Participants With and Without Liver DiseaseWho this might be right forLiver Diseases Novo Nordisk A/S 48
Early research (Phase 1)Study completedNCT01381835What this trial is testingTMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435Who this might be right forHepatitis C Virus Tibotec Pharmaceuticals, Ireland 16
Early research (Phase 1)Study completedNCT06425198What this trial is testingStudy to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentWho this might be right forHepatic ImpairmentHealthy Participants Bristol-Myers Squibb 37
Early research (Phase 1)Study completedNCT04634149What this trial is testingEvaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver ImpairmentWho this might be right forModerate Liver ImpairmentSevere Liver Impairment Bristol-Myers Squibb 16
Early research (Phase 1)Study completedNCT02296853What this trial is testingStudy to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic ImpairmentWho this might be right forHepatitis B Virus Gilead Sciences 20
Early research (Phase 1)Study completedNCT02108639What this trial is testingTo Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination TabletWho this might be right forHepatitis C Bristol-Myers Squibb 41
Early research (Phase 1)Looking for participantsNCT07401862What this trial is testingEloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.Who this might be right forHepatic Insufficiency Eli Lilly and Company 36
Not applicableNot Yet RecruitingNCT07545343What this trial is testingIntegrated Ultrasound-Derived Fat Fraction and 2D/4D HeartAI for Cardiovascular Risk Management in Patients With MASLDWho this might be right forMASLDCardiovascular (CV) RiskSubclinical Cardiovascular Impairments First Affiliated Hospital, Sun Yat-Sen University 700
Early research (Phase 1)Study completedNCT04552808What this trial is testingTo Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy SubjectsWho this might be right forHepatic Impairment Sunshine Lake Pharma Co., Ltd. 16
Early research (Phase 1)Ended earlyNCT03295266What this trial is testingSingle-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)Who this might be right forHepatic InsufficiencyAntibacterial Agents Merck Sharp & Dohme LLC 9
Early research (Phase 1)Study completedNCT03968848What this trial is testingInvestigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its MetaboliteWho this might be right forHepatic ImpairmentHepatic InsufficiencyHealthy Subjects Acerta Pharma BV 16
Early research (Phase 1)Looking for participantsNCT07165002What this trial is testingThe Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver ImpairmentWho this might be right forHealthyHepatic Insufficiency Eli Lilly and Company 32
Early research (Phase 1)Study completedNCT05835180What this trial is testingA Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionWho this might be right forNon-alcoholic SteatohepatitisHepatic ImpairmentCirrhosis Sagimet Biosciences Inc. 48
Early research (Phase 1)Looking for participantsNCT07231991What this trial is testingLearn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionWho this might be right forHealthy Participants Pfizer 24
Early research (Phase 1)Study completedNCT05373953What this trial is testingClinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control SubjectsWho this might be right forChronic Obstructive Pulmonary Disease Chiesi Farmaceutici S.p.A. 44
Early research (Phase 1)Study completedNCT03341884What this trial is testingIpatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy ParticipantsWho this might be right forHepatic Insufficiency Genentech, Inc. 29
Not applicableNot Yet RecruitingNCT07654855What this trial is testingLong-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired SubpopulationsWho this might be right forTransthyretin AmyloidosisTransthyretin Amyloidosis With CardiomyopathyTransthyretin Amyloidosis With Polyneuropathy AstraZeneca 320
Early research (Phase 1)Study completedNCT00976326What this trial is testingA Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver FunctionWho this might be right forDiabetesHealthy Novo Nordisk A/S 12
Early research (Phase 1)Study completedNCT06352528What this trial is testingAssess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic ImpairmentWho this might be right forHepatic ImpairmentHealthy Volunteers Bristol-Myers Squibb 18
Early research (Phase 1)Study completedNCT06535399What this trial is testingStudy to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentWho this might be right forHepatic ImpairmentHealthy Volunteers Celgene 29